First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
Clinical trial NCT05601726 · RECRUITING
Trial details
- NCT number
- NCT05601726
- Sponsor
- Advanced BioDesign
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-08
- Primary completion
- 2026-06-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.